Stockreport

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Canc...

INmune Bio Inc. - Common stock  (INMB) 
PDF on developing treatments that harness the patient's innate immune system to fight disease, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phas [Read more]